Novartis

NVS · NYSE · USD

$141.00−0.04%−$0.05

Close · October 2, 2026

At a glance

Revenue growth
+9.57%
2025 vs 2024
Net income growth
+17.11%
2025 vs 2024
Net margin
24.7%
2024: 23.1%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets122,033118,532110,949107,289104,39599,941102,246103,52497,50594,33499,945112,697
Current assets27,35126,60730,46028,19825,93925,10829,70431,26425,69326,44730,48145,660
Cash and equivalents7,6166,87711,4359,5566,6567,06611,45913,6097,9039,46913,39312,405
Short-term investments2.015.098.011276.071.01,892242528234680411
Receivables9,8549,60210,8338,9849,1768,7259,1318,1508,4808,2519,2477,099
Inventory6,2206,2866,2696,4216,3075,8295,7235,9395,7475,7435,9135,610
Net property, plant and equipment12,26712,23812,35211,99111,82611,08710,87311,20110,62210,54210,92410,344
Goodwill26,76726,81925,56725,55125,55324,96524,75624,93025,23423,06323,34123,416
Other intangible assets42,07440,20929,41129,03729,24027,47626,91527,90227,77526,27226,87926,418
Long-term investments3711,6561,0911,4071,4001,4091,1281,5451,6252,1021,8271,530
Current liabilities31,74831,37427,27832,00031,71431,61928,69228,13227,61229,28826,39048,393
Accounts payable4,2584,3224,4564,5554,5064,2614,5724,0874,1464,0624,9263,870
Long-term debt37,48937,44727,93522,59822,47021,66621,36623,75019,66317,19118,43618,068
Total debt49,01446,99830,73032,02232,63731,27026,66832,15928,98727,284——
Total liabilities80,08779,60564,40062,53762,34161,48958,12060,08355,60354,57853,19574,452
Total equity (incl. minority)41,94638,92746,54944,75242,05438,45244,12643,44141,90239,75646,75038,245
Retained earnings39,64937,25244,72043,51041,52739,83946,56146,29245,83643,83449,64942,333
Minority interest40441541942269.083.080.012416981.083.081.0